Report
EUR 13.72 For Business Accounts Only

BEIJING TONGRENTANG sees a downgrade to Neutral on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of BEIJING TONGRENTANG (CN), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered defensive. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Neutral. As of the analysis date February 4, 2022, the closing price was CNY 41.91 and its target price was estimated at CNY 33.75.
Underlying
Beijing TongRenTang Co. Ltd. Class A

BEIJING TONGRENTANG CO., LTD is a China-based company principally engaged in the production and sales of traditional Chinese patent medicines. The Company's main products consist of liuwei dihuang series, tongren dahuoluo series, tongren niuhuang qingxin series, angong niuhuang series and donkey-hide gelatin series. The Company distributes its products under the brand of Tongrentang. The Company is also involved in the operation of Tongrentang drug stores. The Company distributes its products in domestic market and to overseas markets.

Provider
TheScreener
TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded

 

Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch